Finasteride

[MK-906]



ALX-270-491-M100	100 mg	65.00 USD

ALX-270-491-M500	500 mg	260.00 USD

Inhibitor of 5α-reductase, the enzyme which converts testosterone to the more potent androgen, 5α-dihydrotestosterone. Used as a treatment in benign prostatic hyperplasia and prostate cancer. Also used to treat male pattern hair loss.

Product Specification

Identity:	Identity determined by IR.

Formula:	C₂₃H₃₆N₂O₂

MW:	372.6

Purity:	≥98% (UV)

Appearance:	White to off-white crystalline powder.

CAS:	98319-26-7

MI:	14: 4082

RTECS:	CL5245000

Solubility:	Soluble in DMSO, 100% ethanol, methanol or propanol.

Shipping:	AMBIENT

Long Term Storage:	+4°C

Hazard:	HARMFUL. MAY BE TERATOGENIC.

Please mouse over

Product Literature References

Azasteroids: structure-activity relationships for inhibition of 5 alpha-reductase and of androgen receptor binding: G.H. Rasmusson, et al.; J. Med. Chem. 29, 2298 (1986), Abstract;

Finasteride: the first 5 alpha-reductase inhibitor: S.L. Sudduth & M.J. Koronkowski; Pharmacotherapy 13, 309 (1993), (Review), Abstract;

Finasteride in the treatment of alopecia: J.F. Libecco & W.F. Bergfeld; Expert Opin. Pharmacother. 5, 933 (2004), (Review), Abstract;

A new look at the 5alpha-reductase inhibitor finasteride: D.A. Finn, et al.; CNS Drug Rev. 12, 53 (2006), (Review), Abstract;

Anti-nociceptive and anti-inflammatory properties of 5alpha-reductase inhibitor finasteride in experimental animals: D. Duborija-Kovacevic, et al.; Eur. J. Drug Metab. Pharmacokinet. 33, 181 (2008), Abstract;

Finasteride for prostatic disease: an updated and comprehensive review: C. De Nunzio, et al.; Expert Opin. Drug Metab. Toxicol. 4, 1561 (2008), (Review), Abstract;

Finasteride induces apoptosis via Bcl-2, Bcl-xL, Bax and caspase-3 proteins in LNCaP human prostate cancer cell line: J.M. Golbano, et al.; Int. J. Oncol. 32, 919 (2008), Abstract;